03_03 Metastatic Melanoma
1. Patterns of recurrence and approach to stage IV disease 2. Immunotherapy and BRAF/MEK considerations 3. Cross trial comparisons 4. Later line and emerging therapies for advanced melanoma Citations...
10 Mai 202336min
03_02 Localized Melanoma
1. Background, staging and work-up of regional melanoma 2. Evidence for adjuvant and neoadjuvant immunotherapy 3. Adjuvant BRAF/MEK inhibitor 4. Considerations for stage IIB/IIC disease Citations As...
15 Apr 202326min
03_01 The era of immune checkpoint inhibitors
1. History of Immunotherapy 2. Modern immune checkpoint inhibitors (ICIs) 3. Unique considerations with ICIs 4. Immune related adverse events and immortal time bias in observational studies Citation...
28 Mar 202322min
02_10 BRCA Positive Breast Cancer in the Clinic
1. BRCA 1/2 genes and relation to malignancy 2. Family history taking and identifying patients for genetic testing 3. Risk reduction strategies for breast and ovarian cancer 4. Systemic therapy consid...
14 Mar 202321min
02_09 Triple Negative Breast Cancer
1. Clinical considerations 2. Neoadjuvant and adjuvant regimens 3. Immunotherapy in localized and metastatic disease 4. Later line options in metastatic setting *Erratum- HER-2 Breast cancer <2cm woul...
2 Mar 202327min
02_08 Early HER-2 positive breast cancer
1. Role of adjuvant HER-2 Agents and during of therapy 2. Chemotherapy backbone considerations 3. Pathologic complete response 4. Neoadjuvant systemic therapy and response modified approach Citations ...
14 Feb 202325min
02_07 HER-2 positive breast cancer: Considerations in advanced disease
1. Anti-HER2 agent classes 2. Cleopatra Trial 3. Later line options 4. Leptomeningeal carcinomatosis Citations As always, citations, and sources include education from our respective training program...
19 Jan 202325min
02_06 HER-2 Low Breast Cancer and Sacutuzumab Govetecan
1. HER-2 Testing Algorithm 2. Trastuzumab Deruxtecan in HER-2 Low MBC 3. 2:1 Randomization, Treatment of Provider Choice 4. Sacutuzumab Govetacan for later line TNBC and HR positive MBC Citations As a...
29 Des 202222min
